Properties of CD8 T-cell-recognized neoantigens in different tumor types [0.03%]
不同肿瘤类型中CD8T细胞识别的新生抗原特性
S L C Ketelaars,M M van Buuren,A Gangaev et al.
S L C Ketelaars et al.
Background: Neoantigen-based immunotherapies rely on computational tools predicting peptide immunogenicity based on properties such as its expression level, binding affinity to human leukocyte antigen (HLA), likelihood of...
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors [0.03%]
免疫检查点抑制剂治疗黑色素瘤患者的血栓栓塞事件：发病率及风险因素分析
D C H van Dorst,M M Hofman,R M de Waal et al.
D C H van Dorst et al.
Background: Immune checkpoint inhibitors (ICIs) may increase the incidence of thromboembolisms (TEs). In patients with melanoma, the risk of TE and its association with the disease setting remains largely unknown. This st...
A phase II study of nivolumab, ipilimumab, and radiation in combination with influenza vaccine in patients with pancreatic cancer (INFLUENCE) [0.03%]
一项评估纳武利尤单抗、伊匹木单抗和放疗联合流感疫苗治疗胰腺癌患者的II期研究(INFLUENCE)
I M Chen,S Theile,K Madsen et al.
I M Chen et al.
Background: Considering strong T-cell response from influenza vaccination, we aimed to evaluate ipilimumab, nivolumab, seasonal influenza vaccine, and stereotactic body radiotherapy (SBRT) treatment efficacy in heavily pr...
Assessment of CD73 activity in breast cancer-derived small extracellular vesicles: application to monitoring of patients' responses to immunotherapy [0.03%]
乳腺癌来源的小细胞外囊泡的CD73活性评估：在监测患者对免疫疗法反应中的应用
T L Whiteside,S Sehra,T Chadderton et al.
T L Whiteside et al.
Background: We previously discovered that small extracellular vesicles (sEV) isolated from melanoma cells produce immunosuppressive adenosine (ADO) via the ATP→ADP→AMP→ADO pathway and that CD73 is the 'gateway' ecto-nu...
Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells [0.03%]
具有Vγ9Vδ2CAR-T细胞的CAR-T疗法抗原丢失问题克服策略研究
M Velasco Santiago,P Aehnlich,T M Hulen et al.
M Velasco Santiago et al.
Background: Vγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the t...
M Julve,Y N S Wong,K H J Lim et al.
M Julve et al.
Following the Food and Drug Administration (FDA) approval of lifileucel and afami-cel for patients with advanced melanoma and synovial sarcoma, respectively, there is a need for improved understanding and guidance regarding the management o...
An adjusted droplet digital PCR assay for quantification of vector copy number in CAR-T cell and TCR-T cell products [0.03%]
一种用于CAR-T细胞和TCR-T细胞产品中载体拷贝数定量的校正型液滴数字PCR检测方法
J Ma,S Meyer,J Olweus et al.
J Ma et al.
Background: Genetically engineered T-cell therapy holds immense promise in cancer immunotherapy. These T-cell products are typically engineered by vectors that permanently integrate into the T-cell genome, thus raising co...
Clinical usefulness of anti-α3Gal immunoglobulin E assays for cetuximab-mediated anaphylaxis in head and neck cancer [0.03%]
抗α3Gal免疫球蛋白E检测在头颈部癌症西妥昔单抗介导的过敏反应中的临床应用价值
Y Pointreau,C Freneaux,T Bejan-Angoulvant et al.
Y Pointreau et al.
Background: Fatal anaphylactic reactions to cetuximab remain a clinical issue, although they are associated with preexisting immunoglobulin E (IgE) directed against the galactose-α1,3-galactose epitope (α3Gal). We aimed...
The MELimmune score-prognostic factors for overall survival in advanced melanoma and anti-PD-1 monotherapy-a multicentre, retrospective cohort study [0.03%]
MELimmune评分--晚期黑色素瘤和抗PD-1单药治疗的总体生存预后因素--多中心，回顾性队列研究
S Lobo-Martins,D Martins-Branco,P M Semedo et al.
S Lobo-Martins et al.
Background: Immunotherapy has revolutionized advanced melanoma treatment. Several prognostic factors have been studied to predict survival in this setting. We aimed to develop a prognostic score. ...
Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis [0.03%]
II/III期黑色素瘤中通过无复发生存期的改善来预测总生存获益的挑战与机遇：相关性Meta分析
L Leung,J M Kirkwood,S Srinivasan et al.
L Leung et al.
Background: We evaluated the association between treatment effects on recurrence-free survival (RFS) and overall survival (OS) in randomized controlled trials (RCTs) studying resected stage II/III melanoma. ...